Fate Therapeutics Inc (FATE)

[jondoeuk]

GILD's Kite and Shoreline Bio announce a strategic partnership to develop novel cell therapies across a variety of cancer targets.

Under the terms of the agreement, Shoreline will receive an upfront payment and will be eligible to receive additional payments over $2.3B as well as royalties based on achievement of certain development and commercial milestones.

The collaboration will leverage Shoreline's expertise in iPSC differentiation and genetic reprogramming in combination with Kite's extensive cell therapy development, commercialization and manufacturing expertise.

It will focus initially on CAR-NK targets, with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post deal execution.

https://www.businesswire.com/news/home/20210617005497/en/Kite-and-Shoreline-Biosciences-Enter-Into-Strategic-Partnership-to-Develop-Novel-Allogeneic-Cell-Therapies

Also, https://www.businesswire.com/news/home/20210609005187/en/Shoreline-Biosciences-and-BeiGene-Announce-Strategic-Worldwide-Collaboration-to-Develop-and-Commercialize-Genetically-Modified-Natural-Killer-NK-Cell-Therapies